HUMALOG MIX 50/50 (insulin lispro) by Eli Lilly and Company. Approved for insulin analog [epc]. First approved in 1999.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
HUMALOG MIX 50/50 is a fixed-ratio insulin lispro blend combining rapid-acting and intermediate-acting insulin for glycemic control in Type 1 and Type 2 Diabetes. It works by stimulating peripheral glucose uptake in muscle and fat while inhibiting hepatic glucose production. This premixed formulation simplifies dosing for patients requiring both basal and bolus insulin coverage.
Product facing patent expiration pressure; commercial teams should expect declining market exclusivity and intensified generic competition within 2-3 years.
Insulin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus
A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps
Worked on HUMALOG MIX 50/50 at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on HUMALOG MIX 50/50 offers stable, foundational pharma experience in a mature diabetes market but limited growth trajectory. The LOE Approaching lifecycle stage means career advancement depends on portfolio transition planning and the ability to manage market decline through payer negotiations and cost-containment strategies rather than market expansion.